Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

American Eagle, General Motors, Thor, Quest: U.S. Equity Preview

Don't Miss Out —
Follow us on:

Jan. 20 (Bloomberg) -- Shares of the following companies may have unusual moves in U.S. trading on Jan. 23. Stock symbols are in parentheses, and prices are as of 5 p.m. in New York.

American Eagle Outfitters Inc. (AEO US) fell 0.7 percent to $13.71. Chief Executive Officer James O’Donnell will resign from the teen retailer. The Pittsburgh-based company named Jay Schottenstein executive chairman.

General Motors Co. (GM US): The National Highway Traffic Safety Administration closed its battery safety investigation of the automaker’s Chevy Volts, saying it doesn’t believe they or other electric vehicles pose a greater risk of fire than gasoline-powered vehicles.

Legacy Reserves LP (LGCY US): The Midland, Texas-based oil company boosted its quarterly dividend to 55 cents a share from 54.5 cents.

Thor Industries Inc. (THO US): The recreational-vehicle maker said it agreed to repurchase 1 million shares at $28.50 each in a private transaction from the estate of Wade F.B. Thompson, co-founder and former chief executive officer of the company.

Quest Diagnostics Inc. (DGX US): The Food and Drug Administration authorized the biggest U.S. operator of medical laboratories to offer a new test for infection risk in multiple sclerosis patients taking Elan Corp. (ELN ID) and Biogen Idec Inc.’s Tysabri drug.

Separately, Elan and Biogen Idec won U.S. clearance to modify the label of Tysabri with new safety information that may double the treatment’s worldwide sales.

To contact the reporter on this story: Inyoung Hwang in New York at ihwang7@bloomberg.net.

To contact the editor responsible for this story: Nick Baker at nbaker7@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.